Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akorn, Inc.
Akorn agrees with DoJ to pay $7.9m to settle allegations it deliberately sold three as Rx three ingredients moved to OTC. Mislabeling led Medicare Part D to pay for the drugs for around a year despite the products not being eligible for coverage.
Hydralyte line has 90% share in Australia’s hydration market and accounted for a large share of firm’s overall sales growth in its latest quarter as 28.9% international sales growth to $34.5m offset flat North American results at $242.4m.
CEO Pierre Belichard tells Scrip that the French biotech has enough cash and assets to prosper alone but it is also weighing up a reverse merger that would give Enterome a listing on the NASDAQ.
Akorn says it is concentrating its focus on “targeted avenues of growth” – including human generics and animal care – after divesting its branded ophthalmic portfolio to Théa Pharma.
- Medical Devices
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Hi-Tech Pharmacal
- Oak Pharmaceuticals, Inc., VersaPharm
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.